SCHEMBL4300933

SCHEMBL4300933

Nc1nccc(Oc2ccc3c(C(=O)O)coc3c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.44
FLT1 P17948 2/20 0.44
FLT4 P35916 2/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
KIT P10721 1/20 0.44
LTA4H P09960 1/20 0.39
PIM1 P11309 1/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CSNK2A3 Q8NEV1 1/20 0.37
PDE4B Q07343 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1324462 0.88 KDR (0.44) KDRFLT1FLT4RETPDGFRB
SCHEMBL12124577 0.85 KDR (0.56) KDRFLT1FLT4RETPDGFRB
SCHEMBL1325188 0.81 KDR (0.56) KDRFLT1FLT4RETPDGFRB
SCHEMBL1323962 0.81 KDR (0.51) KDRFLT1FLT4RETPDGFRB
SCHEMBL1325264 0.80 KDR (0.51) KDRFLT1FLT4RETPDGFRB
SCHEMBL4307443 0.79 KDR (0.42) KDRFLT1FLT4RETPDGFRB
SCHEMBL273582 0.79 KDR (0.63) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324859 0.77 KDR (0.75) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324830 0.77 KDR (0.54) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324117 0.77 KDR (0.63) KDRFLT1FLT4RETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US claimed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 WO claimed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 KDR 1285/4885FLT1 1391/4885FLT4 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.